5 IU/L, serum HBsAg level was 2 5 Log IU/mL, and serum hepatitis

5 IU/L, serum HBsAg level was 2.5 Log IU/mL, and serum hepatitis B core-related

antigen www.selleckchem.com/products/cx-4945-silmitasertib.html (HBcrAg) level was 3.0 Log U/mL. [Results] The decline of HBsAg levels over 24 weeks was greater after Peg-IFN alfa-2a treatment than after long-term NA therapy (0.43 vs. 0.12 Log IU/mL). Patients who showed a decline of HBsAg levels tended to have low HBsAg levels at the start of Peg-IFN alfa-2a treatment (1.8 vs. 3.1 Log IU/mL, p = 0.056). Among the 11 patients who completed sequential therapy, HBsAg negativity was achieved in two (18%) and a drug-free status was achieved in eight (73%). Three (27%) of the latter relapsed and required repeated NA, and their ALT levels were constantly within the reference values during PEG-IFN alfa-2a treatment

and no immunostimulatory activity was found. Meanwhile, patients who reached a drug-free status had HBsAg levels of 1.0-3.9 Log U/mL and HBcrAg levels of 2.9-4.3 Log U/mL at the start of sequential therapy. The presence of ≥2 of the following criteria was a useful indicator of a drug-free status: HBsAg level <3.0 Log IU/mL, HBcrAg level <3.0 Log U/mL, and ALT level >60 IU/L during Peg-IFN alfa-2a treatment. [Conclusions] For patients in whom Peg-IFN alfa-2a treatment has a stronger reducing effect on HBsAg levels than NA therapy, sequential therapy decreased HBsAg levels, achieved a drug-free status, and may lead to suppression of hepatocellular carcinoma. Disclosures: MK-8669 order The following people have nothing to disclose: Ken Nishino, Miwa Kawanaka, Jun Nakamura,

Takahito Oka, Noriyo Urata, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro D-malate dehydrogenase Yamada BACKGROUND: Entecavir had been established as one of the first-line drugs for the treatment of chronic hepatitis B due to its high potency and low drug resistance rate. The combination of lamivudine and adefovir, due to cost concerns, are still widely used in Asia, and was previously shown to be effective with low risk of resistance. AIMS: This single-centre, prospective randomized study was designed to compare the efficacy of these two strategies in a real-life clinical setting. METHODS: In this open-label study, patients were randomized into either entecavir (ETV) 1mg daily (n=69) or lamivudine 100mg and adefovir 10mg daily (LAM-ADV) (n=69). Tenofovir rescue was permitted in case of treatment failure. Patients with organ transplant, renal failure and malignancies were excluded. Outcomes measures include undetectable HBV DNA, HBeAg seroconversion, renal impairment, viral resistance, malignancy and mortality. RESULTS: A total of 138 patients were enrolled in our center with a median follow-up period of 60 months. 4 patients from LAM-ADV group and 1 from ETV group withdrew from the study after randomization. At the 60th month, the complete virological response rate (HBV DNA<13.5 IU/ml) was higher in the ETV group compared with the LAM-ADV group (93.1% vs 86.7%, P=0.048).

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>